"Plasmablastic Lymphoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Malignant lymphoma composed of large B lymphoid cells which have the immunophenotype of plasma cells and a predilection for the ORAL CAVITY.
| Descriptor ID |
D000069293
|
| MeSH Number(s) |
C04.557.386.480.150.585.500 C15.604.515.569.480.150.585.500 C20.683.515.761.480.150.585.500
|
| Concept/Terms |
Plasmablastic Lymphoma- Plasmablastic Lymphoma
- Lymphoma, Plasmablastic
- Lymphomas, Plasmablastic
- Plasmablastic Lymphomas
- Plasmablasts Diffuse Large B-cell Lymphoma
- Plasmablasts Diffuse Large B cell Lymphoma
- Plasmablastic Diffuse Large B-cell Lymphoma
- Plasmablastic Diffuse Large B cell Lymphoma
|
Below are MeSH descriptors whose meaning is more general than "Plasmablastic Lymphoma".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, B-Cell [C04.557.386.480.150]
- Lymphoma, Large B-Cell, Diffuse [C04.557.386.480.150.585]
- Plasmablastic Lymphoma [C04.557.386.480.150.585.500]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, B-Cell [C15.604.515.569.480.150]
- Lymphoma, Large B-Cell, Diffuse [C15.604.515.569.480.150.585]
- Plasmablastic Lymphoma [C15.604.515.569.480.150.585.500]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, B-Cell [C20.683.515.761.480.150]
- Lymphoma, Large B-Cell, Diffuse [C20.683.515.761.480.150.585]
- Plasmablastic Lymphoma [C20.683.515.761.480.150.585.500]
Below are MeSH descriptors whose meaning is more specific than "Plasmablastic Lymphoma".
This graph shows the total number of publications written about "Plasmablastic Lymphoma" by people in this website by year, and whether "Plasmablastic Lymphoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 3 | 0 | 3 |
| 2023 | 2 | 0 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Plasmablastic Lymphoma" by people in Profiles.
-
Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 08; 99(8):1586-1594.
-
From the archives of MD Anderson Cancer Center: Plasmablastic lymphoma presenting as a kidney mass in an immunocompetent patient: Case report and literature review. Ann Diagn Pathol. 2023 Dec; 67:152186.
-
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. Am J Hematol. 2023 02; 98(2):300-308.
-
Plasmablastic lymphoma transformation in a patient with Waldenstr?m macroglobulinemia treated with ibrutinib. Br J Haematol. 2021 11; 195(3):466-468.
-
Complete response to pembrolizumab and radiation in a patient with HIV-negative, EBV-positive plasmablastic lymphoma. Am J Hematol. 2021 10 01; 96(10):E390-E392.
-
Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. Haematologica. 2021 04 01; 106(4):1120-1128.
-
Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry. Ann Clin Lab Sci. 2020 Mar; 50(2):213-218.
-
New Onset of Blurred Vision and Floaters. JAMA Ophthalmol. 2019 Feb 01; 137(2):224-225.
-
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019 02; 184(4):679-682.
-
Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course? Leuk Lymphoma. 2018 07; 59(7):1753-1755.